Mirtazapine Ab

Mirtazapine, the active ingredient in Mirtazapine Ab, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapine Ab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under strict quality controls.

Mirtazapine is an antidepressant that acts on noradrenergic and serotonergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depression with insomnia: promotes sleep and alleviates nighttime disturbances. - Depression with anxiety: helps lessen anxiety symptoms associated with depressive episodes.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Hepatotoxicity - Suicidal thoughts or behavior

Before initiating therapy, consider the following safety measures. - Assess hepatic function: adjust use in severe liver impairment. - Monitor weight: significant weight gain may occur. - Evaluate for suicidal ideation: especially during early treatment. - Caution in cardiovascular disease: may cause orthostatic hypotension. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome. - Alcohol and CNS depressants: enhanced sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may increase plasma levels. - CYP inducers (e.g., carbamazepine, rifampin): may reduce efficacy. - Antihistamines: additive sedative effect.